Advancing preclinical drug evaluation through automated 3D imaging for high-throughput screening with kidney organoids
Authors:
- 8 April 2024
- journal article
- research article
- Published by IOP Publishing in Biofabrication
- Vol. 16 (3) , 035003
Abstract
High-throughput drug screening is crucial for advancing healthcare through drug discovery. However, a significant limitation arises from available in vitro models using conventional 2D cell culture, which lack the proper phenotypes and architectures observed in three-dimensional (3D) tissues. Recent advancements in stem cell biology have facilitated the generation of organoids—3D tissue constructs that mimic human organs in vitro. Kidney organoids, derived from human pluripotent stem cells, represent a significant breakthrough in disease representation. They encompass major kidney cell types organized within distinct nephron segments, surrounded by stroma and endothelial cells. This tissue allows for the assessment of structural alterations such as nephron loss, a characteristic of chronic kidney disease. Despite these advantages, the complexity of 3D structures has hindered the use of organoids for large-scale drug screening, and the drug screening pipelines utilizing these complex in vitro models remain to be established for high-throughput screening. In this study, we address the technical limitations of kidney organoids through fully automated 3D imaging, aided by a machine-learning approach for automatic profiling of nephron segment-specific epithelial morphometry. Kidney organoids were exposed to the nephrotoxic agent cisplatin to model severe acute kidney injury. An U.S. Food and Drug Administration (FDA)-approved drug library was tested for therapeutic and nephrotoxicity screening. The fully automated pipeline of 3D image acquisition and analysis identified nephrotoxic or therapeutic drugs during cisplatin chemotherapy. The nephrotoxic potential of these drugs aligned with previous in vivo and human reports. Additionally, Imatinib, a tyrosine kinase inhibitor used in hematological malignancies, was identified as a potential preventive therapy for cisplatin-induced kidney injury. Our proof-of-concept report demonstrates that the automated screening process, using 3D morphometric assays with kidney organoids, enables high-throughput screening for nephrotoxicity and therapeutic assessment in 3D tissue constructs.Keywords
Funding Information
- French National Research Agency (ANR-22-CE14-0077-01)
- NIH (DP2EB029388/DK133821)
This publication has 63 references indexed in Scilit:
- High-Throughput Screening: today’s biochemical and cell-based approachesDrug Discovery Today, 2020
- Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid LeukemiaClinical Lymphoma Myeloma and Leukemia, 2016
- Clarifying Tissue ClearingCell, 2015
- Cisplatin in cancer therapy: Molecular mechanisms of actionEuropean Journal of Pharmacology, 2014
- Olmesartan is More Effective Than Other Angiotensin Receptor Antagonists in Reducing Proteinuria in Patients With Chronic Kidney Disease Other Than Diabetic NephropathyCurrent Therapeutic Research, 2013
- The limitations of renal epithelial cell line HK-2 as a model of drug transporter expression and function in the proximal tubulePflügers Archiv - European Journal of Physiology, 2012
- Patterning a Complex Organ: Branching Morphogenesis and Nephron Segmentation in Kidney DevelopmentDevelopmental Cell, 2010
- Species Differences in Pharmacokinetics and Pharmacodynamics2010
- Cell-Based Assays for High-Throughput ScreeningMolecular Biotechnology, 2010
- Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2Biochemical Pharmacology, 2009